

AC Immune/Genentech to Partner on R&D for Alzheimer's Antibody; \$418M Agree't

AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, of the Roche Group, for the research, development and commercialization of AC Immune's anti-Tau antibodies for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. The agreement is valued at \$400M.